Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts
Surya P. Bhatt(University of Alabama at Birmingham), Raolat M. Abdulai(Sanofi (United States)), Déborah Bauer(Wellesley College), Elizabeth Laws(Sanofi (United States)), Mona Bafadhel(National Institute for Health and Care Excellence), Nicola A. Hanania(Baylor College of Medicine), Jennifer Maloney(Regeneron (United States)), Klaus F. Rabe(Leiden University), Alberto Papi(University of Ferrara), Lacey B. Robinson(Sanofi (United States)), Naimish Patel(Sanofi (United States)), Eric Mortensen(Regeneron (United States)), Dave Singh(University of Manchester), Bolanle Akinlade(Regeneron (United States)), Leda Mannent(Sanofi (France)), George D. Yancopoulos(Regeneron (United States)), Ashish Bansal(Regeneron (United States)), Jeremy Cole, Heribert Staudinger(Sanofi (United States)), Xin Lu(Sanofi (United States)), Claus Vogelmeier(German Center for Lung Research), Stephanie A. Christenson(University of California, San Francisco)
Cited by 452
Related Papers
Vascular-specific growth factors and blood vessel formation
|Nature|2000|3.7k
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary
|American Journal of Respiratory and Critical Care Medicine|2017|3.2k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2k
VEGF-Trap: A VEGF blocker with potent antitumor effects
|Proceedings of the National Academy of Sciences|2002|1.7k
Lebrikizumab Treatment in Adults with Asthma
|New England Journal of Medicine|2011|1.5k